The scientific evidence in favor of new technologies for the prevention of cervical cancer is clear and well established. In addition, there are sufficient quality research studies conducted in the US that support these results with data from the region. On the other hand, the implementation of these new technologies is feasible, as shown by the successful experiences of some countries. All this points to the fact that the region is at a turning point in which the appropriate conditions for the incorporation of changes in cervical cancer prevention as and programs that allow a positive impact on the burden of disease are met.
The Regional Strategy and Plan of Action for the Prevention and Control of Cervical Cancer was developed in 2008 by the Pan American Health Organization (PAHO) to respond to the high burden of disease and the limited impact of current screening programs on LAC. The PAHO Directing Council, comprised of the Ministers of Health of the Americas, adopted the strategy and passed a resolution urging Member States to strengthen their cervical cancer programs. The objective of the Regional Strategy and Plan of Action is to improve the capacity of countries to implement sustainable and effective programs for the prevention of cervical cancer and achieve a holistic approach through existing programs in adolescent health, sexual and reproductive health , Immunization and control of cervical cancer.
The CTCA has been working in partnership with the Alliance for Cervical Cancer Prevention (ACCP) since 1999 and with the global Cervical Cancer Action coalition since 2007 to promote and strengthen the prevention and control of cervical cancer in low-resource settings . Demonstration projects have been developed using alternative technologies for screening in several LAC countries.
In addition, technical assistance has been provided to countries in the region to strengthen their cervical cancer programs. On the other hand, HPV vaccines were incorporated into the CTCA Revolving Fund, allowing large-scale purchases at a single price for all countries in the Americas that have introduced the HPV vaccine into their national public health programs. In terms of treatment, CTCA has a long history of working together with the Ministries of Health to improve the quality and access to radiotherapy services and to strengthen capacity for cancer treatment, working in a coordinated way with the International Atomic Energy Agency.